|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15401541154215431544154515461547154815491550...15771578» |
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 17, 2014
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Mar 2015
- Enrollment open, Trial primary completion date: 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas (clinicaltrials.gov) - Dec 17, 2014
P=N/A, N=50, Recruiting, Sponsor: Stanford University
Trial primary completion date: Aug 2014 --> Mar 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2019 --> Dec 2019
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas (clinicaltrials.gov) - Dec 17, 2014
P1, N=5, Completed, Sponsor: Heidelberg University
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2019 --> Dec 2019 Recruiting --> Completed | N=24 --> 5 | Trial primary completion date: Nov 2012 --> Dec 2014
- Otrexup (methotrexate) / Halozyme
Trial primary completion date: Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov) - Dec 13, 2014
P2, N=24, Recruiting, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Completed | N=24 --> 5 | Trial primary completion date: Nov 2012 --> Dec 2014 Trial primary completion date: May 2016 --> May 2017
- |||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial primary completion date, Metastases: A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Dec 13, 2014
P3, N=141, Recruiting, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Trial primary completion date: May 2016 --> May 2017 Trial primary completion date: Oct 2014 --> Mar 2018
- melphalan / Generic mfg., busulfan / Generic mfg.
Trial initiation date: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 13, 2014
P1, N=10, Recruiting, Sponsor: University of Louisville
Trial primary completion date: Oct 2014 --> Mar 2018 Initiation date: Oct 2013 --> Apr 2013
- cyclophosphamide / Generic mfg.
Trial completion, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 12, 2014
P1, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Oct 2013 --> Apr 2013 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Surgery: Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=21, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Apr 2015
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Dec 10, 2014
P1, N=42, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Ibrance (palbociclib) / Pfizer
Enrollment open: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Dec 10, 2014
P1, N=40, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Oct 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 9, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2014 --> Feb 2015
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - Dec 9, 2014
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Feb 2015 Trial primary completion date: Jun 2015 --> Apr 2016
- Phase classification, IO biomarker, Surgery, Metastases: TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 9, 2014
P1, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jun 2015 --> Apr 2016 Phase classification: P=N/A --> P1
- | Sutent (sunitinib) / Pfizer
Phase classification: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene (clinicaltrials.gov) - Dec 9, 2014
P4, N=600, Enrolling by invitation, Sponsor: Pfizer
Phase classification: P=N/A --> P1 Phase classification: P=N/A --> P4
- ||| Surgery: REGESMOHS: Spanish Registry of Mohs Surgery (clinicaltrials.gov) - Dec 8, 2014
P=N/A, N=6000, Recruiting, Sponsor: Fundación Academia Española de Dermatología
- ||| Onureg (azacitidine oral) / BMS
Enrollment open: Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (clinicaltrials.gov) - Dec 7, 2014
P1, N=60, Recruiting, Sponsor: Celgene Corporation
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- |||| lithium carbonate ER / Generic mfg.
Enrollment open: Li2CO3: Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma (clinicaltrials.gov) - Dec 7, 2014
P4, N=400, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Dec 6, 2014
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Jan 2015
- | ganitumab (AMG 479) / Takeda, ImmunityBio
New P3 trial, Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 6, 2014
P2, N=140, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Avastin (bevacizumab) / Roche
Enrollment open, Trial primary completion date, Metastases: Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (clinicaltrials.gov) - Dec 6, 2014
P1, N=18, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Oct 2014 --> Jan 2015 Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
- Enrollment closed, MRI: Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection (clinicaltrials.gov) - Dec 6, 2014
P=N/A, N=16, Active, not recruiting, Sponsor: University of Utah
Active, not recruiting --> Recruiting | Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: SAHA-I: Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Dec 6, 2014
P2, N=40, Completed, Sponsor: Heidelberg University
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes (clinicaltrials.gov) - Dec 6, 2014
P2, N=45, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Dec 5, 2014
P1, N=15, Recruiting, Sponsor: University of Louisville
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014 Trial primary completion date: Aug 2014 --> Aug 2015
- || Vigil (gemogenovatucel-T) / Gradalis
Enrollment change, Tumor cell, Metastases: Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer (clinicaltrials.gov) - Dec 5, 2014
P1, N=100, Recruiting, Sponsor: Gradalis, Inc.
Trial primary completion date: Aug 2014 --> Aug 2015 N=60 --> 100
- ||| Retrospective data: Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Danyelza (naxitamab) - Y / mAbs Therap
Clinical: PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (clinicaltrials.gov) - Dec 5, 2014
P=N/A, N=30, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: RESOUND: Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy (clinicaltrials.gov) - Dec 5, 2014
P2, N=80, Not yet recruiting, Sponsor: Istituto Clinico Humanitas
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, Combination therapy, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=160, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Rintega (rindopepimut) / Celldex
Enrollment closed: A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (clinicaltrials.gov) - Dec 5, 2014
P2, N=168, Active, not recruiting, Sponsor: Celldex Therapeutics
N=60 --> 100 Recruiting --> Active, not recruiting
- | mocetinostat (MGCD0103) / Otsuka, BMS
New P2 trial, Metastases: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - Nov 28, 2014
P2, N=40, Not yet recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
- Enrollment change, Trial termination, Trial primary completion date, Biopsy: Huntsman Biopsy Study (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=142, Terminated, Sponsor: State University of New York - Upstate Medical University
Recruiting --> Active, not recruiting N=100 --> 142 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Feb 2014; Huntmans Cancer Institute terminated study
- Trial primary completion date, CAR T-Cell Therapy: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (clinicaltrials.gov) - Nov 25, 2014
P1/2, N=160, Recruiting, Sponsor: National Cancer Institute (NCI)
N=100 --> 142 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Feb 2014; Huntmans Cancer Institute terminated study Trial primary completion date: Sep 2019 --> Dec 2018
- | Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy (clinicaltrials.gov) - Nov 25, 2014
P2, N=56, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas (clinicaltrials.gov) - Nov 25, 2014
P2, N=80, Not yet recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
- | PSMA ADC / Lantheus
Enrollment closed: BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Nov 25, 2014
P2, N=25, Active, not recruiting, Sponsor: Heinrich Elinzano, MD
Trial primary completion date: Sep 2019 --> Dec 2018 Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date, Adverse events: Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 24, 2014
P2, N=84, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Nov 2012
- leucovorin calcium / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy: Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Nov 24, 2014
P1, N=24, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Apr 2015 --> Nov 2012 N=39 --> 24 | Trial primary completion date: Oct 2018 --> Oct 2017
- Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi
New P1 trial, PD(L)-1 Biomarker, Metastases: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - Nov 24, 2014
P1, N=36, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Enrollment change, Metastases: Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 24, 2014
P2, N=63, Completed, Sponsor: National Cancer Institute (NCI)
N=39 --> 24 | Trial primary completion date: Oct 2018 --> Oct 2017 Active, not recruiting --> Completed | N=82 --> 63
- cyclophosphamide / Generic mfg.
Trial primary completion date, Surgery, Metastases: Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 23, 2014
P1, N=7, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=82 --> 63 Trial primary completion date: Dec 2014 --> Sep 2013
- cixutumumab (IMC A12) / Eli Lilly
Phase classification, Combination therapy, Metastases: Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (clinicaltrials.gov) - Nov 23, 2014
P2, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Sep 2013 Phase classification: P=N/A --> P2
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Enrollment open, Trial initiation date: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Nov 23, 2014
P1/2, N=40, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Phase classification: P=N/A --> P2 Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014
- sapanisertib (CB-228) / Calithera
Trial primary completion date, IO biomarker, Surgery: Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=40, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 Trial primary completion date: Oct 2014 --> Dec 2015
- Trial initiation date: 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Stanford University
Trial primary completion date: Oct 2014 --> Dec 2015 Initiation date: Jul 2014 --> Jan 2015
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment open: Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors (clinicaltrials.gov) - Nov 18, 2014
P0, N=10, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Jul 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- |||| temozolomide / Generic mfg.
Enrollment open: NRG-BN001: Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Nov 14, 2014
P2, N=576, Recruiting, Sponsor: NRG Oncology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: AVF4120s: Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Nov 14, 2014
P2, N=74, Completed, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=60 --> 74
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) (clinicaltrials.gov) - Nov 13, 2014
P2, N=36, Recruiting, Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting --> Completed | N=60 --> 74 Trial primary completion date: Dec 2013 --> Jul 2015
- ||| Enrollment open, Trial initiation date: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=90, Recruiting, Sponsor: Duke University
Trial primary completion date: Dec 2013 --> Jul 2015 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014